- Home
- MMI vs PHAT Comparison
MMI vs PHAT Comparison
Compare MMI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMI | PHAT |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 969.8M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MMI | PHAT |
|---|---|---|
| Price | $32.32 | $8.87 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $28.00 | $19.83 |
| AVG Volume (30 Days) | 113.6K | ★ 1.7M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ 84.38 | 42.72 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $719,700,000.00 | $175,110,000.00 |
| Revenue This Year | $14.04 | $93.04 |
| Revenue Next Year | $11.35 | $58.91 |
| P/E Ratio | $1,635.00 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $24.43 | $8.21 |
| 52 Week High | $33.62 | $18.31 |
Technical Indicators
Market Signals| Indicator | MMI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 40.97 |
| Support Level | $29.45 | $8.78 |
| Resistance Level | $32.54 | $12.07 |
| Average True Range (ATR) | 0.90 | 0.49 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 69.47 | 41.37 |
Price Performance
Historical ComparisonAbout MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.